It isn't the same. So don't draw conclusions. Definitely get a second phase 3 trial completed before you even think about approval.
“We see that the hypothesis is reinforced today with the news from another important company,” Vounatsos said of the results from Lilly. But the read-through between Lilly’s treatment, called donanemab, and aducanumab appears tenuous. The two treatments target different forms of amyloid, and their respective trials used different measurements of cognitive ability. Furthermore, Lilly’s study was more stringent in patient recruitment, enrolling only those who had measurable levels of brain amyloid and low levels of a different protein called tau. Biogen’s earlier studies did not disqualify patients based on tau.
